Pathway Financial Advisors LLC Sells 3,588 Shares of Abbott Laboratories $ABT

Key Points

• Pathway Financial Advisors LLC sold 3,588 shares of Abbott Laboratories, reducing its holdings by 50.7%, leaving it with 3,490 shares valued at $475,000.
• Abbott Laboratories reported a Q2 2025 guidance of 5.100-5.200 EPS, while its recent earnings results met analysts' estimates with a revenue of $11.14 billion.
• The company has announced a quarterly dividend of $0.59 per share, set to be paid on November 17th, representing an annualized yield of 1.8%.

Pathway Financial Advisors LLC lessened its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 50.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,490 shares of the healthcare product maker's stock after selling 3,588 shares during the quarter. Pathway Financial Advisors LLC's holdings in Abbott Laboratories were worth $475,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ABT. Edge Financial Advisors LLC boosted its position in shares of Abbott Laboratories by 3.3% during the first quarter. Edge Financial Advisors LLC now owns 2,530 shares of the healthcare product maker's stock worth $336,000 after acquiring an additional 81 shares during the last quarter. Avanza Fonder AB boosted its holdings in shares of Abbott Laboratories by 0.4% during the 2nd quarter. Avanza Fonder AB now owns 168,401 shares of the healthcare product maker's stock valued at $22,904,000 after purchasing an additional 655 shares during the last quarter. Madrona Financial Services LLC grew its position in shares of Abbott Laboratories by 9.7% during the second quarter. Madrona Financial Services LLC now owns 1,726 shares of the healthcare product maker's stock valued at $235,000 after purchasing an additional 152 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Abbott Laboratories by 12.4% in the second quarter. Janney Montgomery Scott LLC now owns 669,868 shares of the healthcare product maker's stock worth $91,109,000 after purchasing an additional 73,780 shares during the last quarter. Finally, SageView Advisory Group LLC boosted its stake in Abbott Laboratories by 18.6% during the first quarter. SageView Advisory Group LLC now owns 18,294 shares of the healthcare product maker's stock valued at $2,427,000 after buying an additional 2,873 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company's stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This represents a 9.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.46% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research note on Monday, June 16th. Wells Fargo & Company reduced their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research report on Friday, July 18th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and increased their price objective for the company from $143.00 to $145.00 in a research report on Friday, July 18th. BTIG Research reduced their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating on the stock in a report on Friday, July 18th. Finally, Leerink Partners began coverage on shares of Abbott Laboratories in a report on Monday, June 16th. They issued a "market perform" rating and a $143.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $146.17.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $132.30 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. The firm has a market capitalization of $230.26 billion, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company's 50-day moving average is $132.54 and its 200 day moving average is $131.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts' expectations of $11.01 billion. During the same quarter in the prior year, the firm posted $1.14 earnings per share. The company's quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.